Pluristem Therapeutics Inc. (PSTI) - 10-K Summary
Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (formerly Pluristem Life Systems Inc.)
Reporting Period: Fiscal year ended June 30, 2008
Business Model: A bio-therapeutics company in the development stage, focused on commercializing non-personalized (allogeneic) cell therapy products derived from human placenta. The company utilizes a proprietary 3D bioreactor system (PluriX™) to expand placental adherent stromal cells (PLX cells).
Key Products in Development: PLX-PAD (Peripheral Artery Disease), PLX-BMT (Bone Marrow Transplantation), PLX-STROKE (Ischemic Stroke), PLX-IBD (Inflammatory Bowel Disease), and PLX-MS (Multiple Sclerosis).
Operational Status: The company has no commercial revenue and is dependent on external financing. It operates primarily from facilities in Haifa, Israel.
Key Financial Metrics
| Metric (in thousands USD) | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,498) | $(8,429) |
| Loss Per Share (Basic & Diluted) | $(1.63) | $(5.84) |
| Research & Development Expenses (Net) | $4,393 | $2,549 |
| General & Administrative Expenses | $6,036 | $3,726 |
| Cash and Cash Equivalents (End of Period) | $323 | $1,653 |
| Marketable Securities | $1,185 | $3,758 |
| Total Current Assets | $2,107 | $6,053 |
| Total Current Liabilities | $1,072 | $733 |
| Working Capital | $1,035 | $5,320 |
| Accumulated Deficit | $(26,016) | $(15,518) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately 25% to $10.5 million, driven primarily by a $1.46 million increase in stock-based compensation and higher operational costs.
- R&D Expansion: Net R&D expenses rose 72% to $4.4 million due to increased employee headcount, final pre-clinical studies under GLP conditions, and the revaluation of the Israeli Shekel against the US Dollar.
- G&A Growth: General and administrative expenses increased 62% to $6.0 million, largely due to higher stock-based compensation ($3.16 million vs. $1.93 million) and increased legal/investor relations costs.
- Cash Position: Cash and cash equivalents decreased by $1.33 million to $323,000. This was due to $4.5 million used in operating activities, partially offset by $1.3 million provided by investing activities (sale of marketable securities) and $1.9 million from financing activities.
- Stock Split: A 1-for-200 reverse stock split was effected on November 26, 2007. All share and per-share data in the filing are adjusted retroactively.
Guidance, Outlook, and Risks
- Going Concern: The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, an accumulated deficit of $26 million, and a lack of revenue. Continued operations depend on raising additional capital.
- Capital Requirements: Management estimates cash expenses for the next 12 months to be approximately $6 million ($4 million for R&D and $2 million for G&A). The company believes it has sufficient funds to operate for at least two additional fiscal quarters but will need to raise additional funds before generating cash flow from operations.
- Strategic Milestones: Key objectives for the next 12 months include filing the IND package with the FDA, scaling up bioreactor operations to commercial capabilities, and initiating Phase I clinical trials for PLX-PAD (PAD indication) in the US and Germany.
- Regulatory Progress: The FDA accepted the Pre-IND for PLX-BMT and approved the synopsis for a Phase I clinical trial for PLX-PAD. The company is completing the IND package for PLX-PAD.
- Risk Factors:
- Financing Risk: Inability to secure additional financing could force a cessation of operations.
- Regulatory Risk: No assurance that products will receive FDA or other regulatory approvals; clinical trials may fail.
- Market Risk: Exposure to fluctuations in the Israeli Shekel (NIS) and Euro, which impacts operating costs.
- Legal/Contractual Risk: Potential conflict with a prior financing agreement regarding minimum share sale prices following the reverse stock split.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $323,000 cash balance plus $1.185 million in marketable securities against the estimated $6 million annual burn rate.
- Financing Status: Confirm the status of subsequent equity offerings mentioned in the filing (August and September 2008 transactions) and whether they have been closed successfully.
- Regulatory Timeline: Monitor the submission and acceptance of the IND package for PLX-PAD by the FDA, as this is the critical path to clinical trials.
- Stock-Based Compensation: Review the impact of the $4.76 million in stock-based compensation (employees and consultants) on future dilution and cash flow projections.
- Going Concern Opinion: Assess the company's ability to secure the necessary capital to avoid the "substantial doubt" noted by auditors.